Pre-Clinical Development and Oncology Advisor
Dr. Mark Anderson is a cancer biologist and drug developer with over 25 years of experience in the biotechnology and pharmaceutical industries. He has led drug discovery teams focused on the preclinical development of biologically based therapeutics for cancer and has advanced multiple novel agents from discovery to clinical testing. Mark is currently Vice President at Genome Profiling LLC, a functional genomics company using a proprietary machine learning algorithm to discover DNA methylation based biomarkers for disease diagnosis and drug response prediction. He also serves as a scientific advisor and consultant to drug development accelerators, venture capital firms, and public and private biotechnology companies through his consulting firm.
Prior to joining the EDI Scientific Advisory Board Mark
spent several years in the biotechnology industry discovering and developing innate immune stimulants and anti-cancer agents at Magainin Pharmaceuticals, followed by 15 years at Johnson & Johnson leading teams developing anti-cancer biologics, most recently as Scientific Director of Oncology Research at Janssen Pharmaceuticals. He led a team at Janssen, in collaboration with GenMab, that discovered and developed JNJ-61186372, an EGFR-cMet targeting bispecific antibody with encouraging anti-tumor activity in ongoing lung cancer clinical trials. Mark’s expertise includes strategic R&D and business planning, the development of antibodies, antibody drug conjugates, novel biologic scaffolds, immuno-oncology agents, and bispecific antibodies for the treatment of cancer. Mark received his Ph.D. in Biological Chemistry from the University of Michigan in Ann Arbor and conducted his postdoctoral training at Merck Research Laboratories in West Point, Pennsylvania.